During the past years transcatheter aortic valve implantation (TAVI) has evolved to a standard technique for the treatment of high risk patients suffering from severe aortic stenosis. Worldwide the number of TAVI procedures is increasing exponentially. In this context both the transapical antegrade (TA) and the transfemoral retrograde (TF) approach are predominantly used and can be considered as safe and reproducible access sites for TAVI interventions. As a new technology TAVI is in a constant progress regarding the development of new devices. While in the first years only the Edwards SAPIEN™ and the Medtronic CoreValve™ prostheses were commercial available, recently additional devices obtained CE-mark approval and others have entered initial clinical trials. In addition to enhance the treatment options in general, the main driving factor to further develop new device iterations is to solve the drawbacks of the current TAVI systems: paravalvular leaks, occurrence of AV-blocks and the lack of full repositionability. © 2013 Bentham Science Publishers.
CITATION STYLE
Blumenstein, J., Liebetrau, C., Linden, A., Moellmann, H., Walther, T., & Kempfert, J. (2014). Recent Advances in Transcatheter Aortic Valve Implantation: Novel Devices and Potential Shortcomings. Current Cardiology Reviews, 9(4), 274–280. https://doi.org/10.2174/1573403x09666131202124807
Mendeley helps you to discover research relevant for your work.